PL306157A1 - 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine[3-isopropyl-5-(2-methoxyethyl)]dicarboxylate, method of obtaining same, drugs containing it and method of making such drugs - Google Patents
4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine[3-isopropyl-5-(2-methoxyethyl)]dicarboxylate, method of obtaining same, drugs containing it and method of making such drugsInfo
- Publication number
- PL306157A1 PL306157A1 PL94306157A PL30615794A PL306157A1 PL 306157 A1 PL306157 A1 PL 306157A1 PL 94306157 A PL94306157 A PL 94306157A PL 30615794 A PL30615794 A PL 30615794A PL 306157 A1 PL306157 A1 PL 306157A1
- Authority
- PL
- Poland
- Prior art keywords
- drugs
- dimethylpyridine
- cyanophenyl
- methoxyethyl
- dihydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 2
- 229940079593 drug Drugs 0.000 title 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- -1 compound rac-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarb oxylate Chemical class 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Abstract
The present invention relates to the compound rac-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarb oxylate and its pure enantiomers, to processes for the preparation thereof and to the use thereof as pharmaceutical, in particular for treatment of cerebral and neuronal disorders and to an intermediate for the preparation thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4342194A DE4342194A1 (en) | 1993-12-10 | 1993-12-10 | New pyridine-3,5-di:carboxylic acid deriv. |
| DE19944424677 DE4424677A1 (en) | 1994-07-13 | 1994-07-13 | New pyridine-3,5-di:carboxylic acid deriv. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL306157A1 true PL306157A1 (en) | 1995-06-12 |
| PL179973B1 PL179973B1 (en) | 2000-11-30 |
Family
ID=25931956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL94306157A PL179973B1 (en) | 1993-12-10 | 1994-12-07 | [3-isopropyl-5-(2-methoxyethyl)]-dicarboxylate-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethylpyridine and method for producing [3-isopropyl-5-( 2-methoxyethyl)]-dicarboxylate 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethylpyridine EN EN EN EN EN |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US5665740A (en) |
| EP (1) | EP0657430B1 (en) |
| JP (1) | JP3751041B2 (en) |
| KR (1) | KR100332325B1 (en) |
| CN (2) | CN1056606C (en) |
| AT (1) | ATE180774T1 (en) |
| AU (1) | AU686976B2 (en) |
| BG (1) | BG62487B1 (en) |
| CA (1) | CA2137525C (en) |
| CO (1) | CO4290426A1 (en) |
| CU (1) | CU22713A3 (en) |
| CZ (1) | CZ286065B6 (en) |
| DE (1) | DE59408350D1 (en) |
| DK (1) | DK0657430T3 (en) |
| DZ (1) | DZ1831A1 (en) |
| EE (1) | EE03192B1 (en) |
| ES (1) | ES2132308T3 (en) |
| FI (1) | FI105681B (en) |
| GR (1) | GR3030436T3 (en) |
| HR (1) | HRP940967B1 (en) |
| HU (1) | HU215593B (en) |
| IL (1) | IL111922A (en) |
| LV (1) | LV11321B (en) |
| MA (1) | MA23392A1 (en) |
| MY (1) | MY111976A (en) |
| NO (1) | NO302362B1 (en) |
| NZ (1) | NZ270087A (en) |
| PL (1) | PL179973B1 (en) |
| RO (1) | RO115800B1 (en) |
| SA (1) | SA95160078B1 (en) |
| SK (1) | SK282399B6 (en) |
| SV (1) | SV1994000072A (en) |
| TN (1) | TNSN94127A1 (en) |
| TW (1) | TW412529B (en) |
| YU (1) | YU48920B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1952824A1 (en) * | 2003-11-21 | 2008-08-06 | Memory Pharmaceuticals Corporation | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| WO2008058234A2 (en) * | 2006-11-08 | 2008-05-15 | Memory Pharmaceuticals Corporation | Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility |
| US11512052B2 (en) * | 2017-11-21 | 2022-11-29 | Icahn School Of Medicine At Mount Sinai | Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963188A1 (en) * | 1969-12-17 | 1971-06-24 | Bayer Ag | New cyanophenyl-1,4-dihydropyridine derivatives |
| DE2117572C3 (en) * | 1971-04-10 | 1980-03-20 | Bayer Ag, 5090 Leverkusen | Asymmetrical 1,4-dihydropyridine ^ -dicarboxylic acid esters, process for their preparation and their use as pharmaceuticals |
| US3932646A (en) * | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate |
| DE2508181A1 (en) * | 1975-02-26 | 1976-09-09 | Bayer Ag | 1,4-DIHYDROPYRIDINCARBONIC ACID ARAL KYLESTER, METHOD FOR MANUFACTURING AND USING THEY AS A MEDICINAL PRODUCT |
| DE2815578C2 (en) * | 1978-04-11 | 1986-01-16 | Bayer Ag, 5090 Leverkusen | New pharmaceutical use of nimodipine |
| DE2935451A1 (en) * | 1979-09-01 | 1981-03-19 | Bayer Ag, 5090 Leverkusen | OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
| DE3208628A1 (en) * | 1982-03-10 | 1983-09-22 | Bayer Ag, 5090 Leverkusen | NEW COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
| DE3239273A1 (en) * | 1982-10-23 | 1984-04-26 | Bayer Ag, 5090 Leverkusen | TETRAHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS |
| US5137889A (en) * | 1983-12-02 | 1992-08-11 | Otsuka Pharmaceutical Co., Ltd. | Dihydropyridine derivatives and process for preparing the same |
| DE3718398A1 (en) * | 1987-06-02 | 1988-12-22 | Troponwerke Gmbh & Co Kg | NEW COMBINATION DEVICES WITH ANTI-DEPRESSIVE EFFECT |
| US5114946A (en) * | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| DE3806277A1 (en) * | 1988-02-27 | 1989-09-07 | Troponwerke Gmbh & Co Kg | USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES |
| DE4011695A1 (en) * | 1990-04-11 | 1991-10-17 | Bayer Ag | USE OF N-ALKYLATED 1,4-DIHYDROPYRIDE INDICARBOXIC ACID ESTERS AS DRUGS, NEW COMPOUNDS AND METHOD FOR THEIR PREPARATION |
| FR2671349B1 (en) * | 1991-01-09 | 1993-04-23 | Lafon Labor | NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM. |
| DE4125271A1 (en) * | 1991-07-31 | 1993-02-11 | Bayer Ag | NEW N-ALKYLATED 1,4-DIHYDROPYRIDINDICARBONIC ACID ESTERS |
-
1994
- 1994-11-22 EE EE9400393A patent/EE03192B1/en not_active IP Right Cessation
- 1994-11-28 ES ES94118671T patent/ES2132308T3/en not_active Expired - Lifetime
- 1994-11-28 EP EP94118671A patent/EP0657430B1/en not_active Expired - Lifetime
- 1994-11-28 AT AT94118671T patent/ATE180774T1/en active
- 1994-11-28 DK DK94118671T patent/DK0657430T3/en active
- 1994-11-28 DE DE59408350T patent/DE59408350D1/en not_active Expired - Lifetime
- 1994-12-01 HR HRP4424677.3A patent/HRP940967B1/en not_active IP Right Cessation
- 1994-12-02 CU CU13794A patent/CU22713A3/en unknown
- 1994-12-02 CO CO94055078A patent/CO4290426A1/en unknown
- 1994-12-02 US US08/348,436 patent/US5665740A/en not_active Expired - Lifetime
- 1994-12-06 RO RO94-01950A patent/RO115800B1/en unknown
- 1994-12-06 JP JP32981994A patent/JP3751041B2/en not_active Expired - Fee Related
- 1994-12-07 CA CA002137525A patent/CA2137525C/en not_active Expired - Fee Related
- 1994-12-07 PL PL94306157A patent/PL179973B1/en not_active IP Right Cessation
- 1994-12-07 IL IL11192294A patent/IL111922A/en not_active IP Right Cessation
- 1994-12-07 SK SK1516-94A patent/SK282399B6/en not_active IP Right Cessation
- 1994-12-07 NZ NZ270087A patent/NZ270087A/en not_active IP Right Cessation
- 1994-12-07 DZ DZ940128A patent/DZ1831A1/en active
- 1994-12-07 TN TNTNSN94127A patent/TNSN94127A1/en unknown
- 1994-12-08 CZ CZ19943093A patent/CZ286065B6/en not_active IP Right Cessation
- 1994-12-08 YU YU71794A patent/YU48920B/en unknown
- 1994-12-08 SV SV1994000072A patent/SV1994000072A/en not_active Application Discontinuation
- 1994-12-08 BG BG99249A patent/BG62487B1/en unknown
- 1994-12-08 FI FI945777A patent/FI105681B/en not_active IP Right Cessation
- 1994-12-08 AU AU80306/94A patent/AU686976B2/en not_active Ceased
- 1994-12-09 MY MYPI94003289A patent/MY111976A/en unknown
- 1994-12-09 NO NO944787A patent/NO302362B1/en not_active IP Right Cessation
- 1994-12-09 LV LVP-94-242A patent/LV11321B/en unknown
- 1994-12-09 KR KR1019940033434A patent/KR100332325B1/en not_active Expired - Fee Related
- 1994-12-09 MA MA23720A patent/MA23392A1/en unknown
- 1994-12-09 HU HU9403551A patent/HU215593B/en not_active IP Right Cessation
- 1994-12-09 CN CN94112892A patent/CN1056606C/en not_active Expired - Fee Related
-
1995
- 1995-02-14 TW TW084101294A patent/TW412529B/en not_active IP Right Cessation
- 1995-06-28 SA SA95160078A patent/SA95160078B1/en unknown
-
1999
- 1999-06-09 GR GR990401523T patent/GR3030436T3/en unknown
- 1999-06-30 CN CN99108967A patent/CN1124258C/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE348829T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING CNS DISORDERS OR OTHER DISEASES | |
| DE60134453D1 (en) | Pharmaceutical compositions for the treatment of CNS and other diseases | |
| WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
| AU6001990A (en) | 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents | |
| PL306157A1 (en) | 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine[3-isopropyl-5-(2-methoxyethyl)]dicarboxylate, method of obtaining same, drugs containing it and method of making such drugs | |
| EP0383171A3 (en) | 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders | |
| EP0435153A3 (en) | R-(-)-1-(5-hydroxyhexyl)-3-methyl-7-propylxanthin, process for its preparation and medicines containing it | |
| CA2130563A1 (en) | 2,6-Methano-2H-Quinolizin Derivative as 5-HT3-Receptor Antagonist | |
| ZA898274B (en) | 2-aminocarboxylic acids and their derivatives,processes for their preparation and their use as medicaments | |
| DK0950053T3 (en) | New benzoylalkyl, 1,2,3,6-tetrahydropyridine derivatives | |
| SE9203857D0 (en) | USE OF AN ENANTIOMERIC DIHYDROPYRIDINE | |
| WO2004091522A3 (en) | Method for treating neurodegenerative disorders | |
| EP0402733A3 (en) | Agent for the treatment of central nervous system illnesses and for the enhancement of cerebral blood flow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20111207 |